Rise in patient reporting boosts EU drug safety signals
This article was originally published in SRA
Executive Summary
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area rose by more than 50% as a result of greater public awareness of the importance of such reporting.
You may also be interested in...
Hydroxyethyl-Starch Solutions To Be Pulled From EU Market
Hydroxyethyl-starch solutions are being suspended from the EU following the failure of several safety measures that were introduced to prevent their use in certain high-risk patient groups.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.